Tudor I. Oprea

28.7k total citations · 10 hit papers
244 papers, 18.6k citations indexed

About

Tudor I. Oprea is a scholar working on Molecular Biology, Computational Theory and Mathematics and Genetics. According to data from OpenAlex, Tudor I. Oprea has authored 244 papers receiving a total of 18.6k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Molecular Biology, 115 papers in Computational Theory and Mathematics and 30 papers in Genetics. Recurrent topics in Tudor I. Oprea's work include Computational Drug Discovery Methods (115 papers), Pharmacogenetics and Drug Metabolism (25 papers) and Analytical Chemistry and Chromatography (24 papers). Tudor I. Oprea is often cited by papers focused on Computational Drug Discovery Methods (115 papers), Pharmacogenetics and Drug Metabolism (25 papers) and Analytical Chemistry and Chromatography (24 papers). Tudor I. Oprea collaborates with scholars based in United States, Sweden and Denmark. Tudor I. Oprea's co-authors include Cristian Bologa, Oleg Ursu, Larry A. Sklar, Eric R. Prossnitz, Leslie Z. Benet, A. M. Davis, Jeffrey B. Arterburn, Paul D. Leeson, Simon J. Teague and Fabio Broccatelli and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Chemical Society Reviews.

In The Last Decade

Tudor I. Oprea

239 papers receiving 18.0k citations

Hit Papers

A comprehensive map of molecula... 1999 2026 2008 2017 2016 2006 1999 2016 2001 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A comprehensive map of molecular drug targets
    2016 1.6k citations Oleg Ursu, Anna Gaulton et al. profile →
  2. Virtual and biomolecular screening converge on a selective agonist for GPR30
    2006 692 citations Cristian Bologa, Susan Young et al. profile →
  3. The Design of Leadlike Combinatorial Libraries
    1999 604 citations Tudor I. Oprea et al. profile →
  4. BDDCS, the Rule of 5 and drugability
    2016 597 citations Oleg Ursu, Tudor I. Oprea et al. profile →
  5. Is There a Difference between Leads and Drugs? A Historical Perspective
    2001 552 citations Tudor I. Oprea et al. profile →
  6. QSAR without borders
    2020 547 citations Eugene Muratov, Jürgen Bajorath et al. Chemical Society Reviews profile →
  7. BDDCS Applied to Over 900 Drugs
    2011 520 citations Tudor I. Oprea et al. profile →
  8. Property distribution of drug-related chemical databases*
    2000 502 citations Tudor I. Oprea profile →
  9. Estrogen Signaling through the Transmembrane G Protein–Coupled Receptor GPR30
    2008 501 citations Eric R. Prossnitz, Jeffrey B. Arterburn et al. profile →
  10. How many rare diseases are there?
    2019 279 citations Cristian Bologa, Giovanni Bocci et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tudor I. Oprea United States 68 9.4k 6.6k 3.3k 2.3k 1.9k 244 18.6k
Ruben Abagyan United States 83 21.8k 2.3× 5.7k 0.9× 1.5k 0.5× 2.2k 1.0× 1.6k 0.8× 347 30.7k
Jian Zhang China 84 17.6k 1.9× 2.8k 0.4× 2.1k 0.7× 1.7k 0.7× 1.0k 0.5× 1.1k 31.2k
Sean Ekins United States 69 6.1k 0.6× 6.3k 0.9× 904 0.3× 1.2k 0.5× 1.1k 0.6× 383 15.6k
Hualiang Jiang China 80 17.1k 1.8× 6.7k 1.0× 854 0.3× 6.4k 2.8× 2.8k 1.5× 713 30.2k
Oleg Trott United States 7 14.2k 1.5× 6.5k 1.0× 811 0.2× 6.2k 2.7× 2.9k 1.5× 7 27.3k
Michel F. Sanner United States 28 14.0k 1.5× 6.1k 0.9× 762 0.2× 6.0k 2.6× 2.5k 1.3× 53 25.6k
Stephen H. Bryant United States 55 14.1k 1.5× 4.9k 0.7× 1.6k 0.5× 1.1k 0.5× 1.4k 0.7× 156 21.5k
John P. Overington United Kingdom 41 11.7k 1.2× 6.9k 1.0× 828 0.3× 1.5k 0.6× 1.6k 0.8× 97 16.7k
Holger Gohlke Germany 49 16.4k 1.7× 4.9k 0.7× 1.0k 0.3× 2.5k 1.1× 1.2k 0.6× 283 23.1k
Roderick E. Hubbard United Kingdom 43 7.7k 0.8× 2.5k 0.4× 3.0k 0.9× 1.5k 0.6× 617 0.3× 110 11.9k

Countries citing papers authored by Tudor I. Oprea

Since Specialization
Citations

This map shows the geographic impact of Tudor I. Oprea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tudor I. Oprea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tudor I. Oprea more than expected).

Fields of papers citing papers by Tudor I. Oprea

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tudor I. Oprea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tudor I. Oprea. The network helps show where Tudor I. Oprea may publish in the future.

Co-authorship network of co-authors of Tudor I. Oprea

This figure shows the co-authorship network connecting the top 25 collaborators of Tudor I. Oprea. A scholar is included among the top collaborators of Tudor I. Oprea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tudor I. Oprea. Tudor I. Oprea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Metzger, Vincent T., Daniel C. Cannon, Jeremy J. Yang, et al.. (2024). TIN-X version 3: update with expanded dataset and modernized architecture for enhanced illumination of understudied targets. PeerJ. 12. e17470–e17470. 1 indexed citations
2.
Magariños, María Paula, Anna Gaulton, Eloy Félix, et al.. (2023). Illuminating the druggable genome through patent bioactivity data. PeerJ. 11. e15153–e15153. 6 indexed citations
3.
Junge, Alexander, et al.. (2022). Diseases 2.0: a weekly updated database of disease–gene associations from text mining and data integration. Database. 2022. 59 indexed citations
4.
Yang, Jeremy J., Christophe G Lambert, Cristian Bologa, et al.. (2021). TIGA: target illumination GWAS analytics. Bioinformatics. 37(21). 3865–3873. 8 indexed citations
5.
Muratov, Eugene, Jürgen Bajorath, Robert P. Sheridan, et al.. (2020). Correction: QSAR without borders. Chemical Society Reviews. 49(11). 3716–3716. 17 indexed citations
6.
Muratov, Eugene, Jürgen Bajorath, Robert P. Sheridan, et al.. (2020). QSAR without borders. Chemical Society Reviews. 49(11). 3525–3564. 547 indexed citations breakdown →
7.
Sheils, Timothy, Stephen L. Mathias, Keith J. Kelleher, et al.. (2020). TCRD and Pharos 2021: mining the human proteome for disease biology. Nucleic Acids Research. 49(D1). D1334–D1346. 90 indexed citations
8.
Oprea, Tudor I., et al.. (2019). The human endogenous metabolome as a pharmacology baseline for drug discovery. Drug Discovery Today. 24(9). 1806–1820. 8 indexed citations
9.
Guo, Yuna, S. Ray Kenney, Linda S. Cook, et al.. (2015). A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients. Clinical Cancer Research. 21(22). 5064–5072. 39 indexed citations
10.
Christianson, Dawn R., Andrey S. Dobroff, Bettina Proneth, et al.. (2015). Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. Proceedings of the National Academy of Sciences. 112(8). 2521–2526. 12 indexed citations
11.
Jensen, Anders Boeck, Pope Moseley, Tudor I. Oprea, et al.. (2014). Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients. Nature Communications. 5(1). 28–30. 257 indexed citations
12.
Strouse, J. Jacob, Irena Ivnitski‐Steele, Anna Waller, et al.. (2013). Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters. Analytical Biochemistry. 437(1). 77–87. 50 indexed citations
13.
Williamson, Elizabeth A., Leah A. Damiani, Andrei Leitão, et al.. (2012). Targeting the Transposase Domain of the DNA Repair Component Metnase to Enhance Chemotherapy. Cancer Research. 72(23). 6200–6208. 30 indexed citations
14.
Ariazi, Eric A., Eugen Brailoiu, Smitha Yerrum, et al.. (2010). The G Protein–Coupled Receptor GPR30 Inhibits Proliferation of Estrogen Receptor–Positive Breast Cancer Cells. Cancer Research. 70(3). 1184–1194. 204 indexed citations
15.
Saunders, Matthew, Steven W. Graves, Larry A. Sklar, Tudor I. Oprea, & Bruce S. Edwards. (2009). High-Throughput Multiplex Flow Cytometry Screening for Botulinum Neurotoxin Type A Light Chain Protease Inhibitors. Assay and Drug Development Technologies. 8(1). 37–46. 17 indexed citations
16.
Haynes, Mark K., J. Jacob Strouse, Anna Waller, et al.. (2009). Detection of Intracellular Granularity Induction in Prostate Cancer Cell Lines by Small Molecules Using the HyperCyt® High-Throughput Flow Cytometry System. SLAS DISCOVERY. 14(6). 596–609. 21 indexed citations
17.
Chigaev, Alexandre, Anna Waller, D. Włodek, et al.. (2009). Conformational mAb as a Tool for Integrin Ligand Discovery. Assay and Drug Development Technologies. 7(5). 507–515. 14 indexed citations
18.
Oprea, Tudor I.. (2008). 2-Killing vector fields on Riemannian manifolds.. 13(1). 87–92. 13 indexed citations
19.
Ivnitski‐Steele, Irena, Richard A. Larson, Debbie M. Lovato, et al.. (2008). High-Throughput Flow Cytometry to Detect Selective Inhibitors of ABCB1, ABCC1, and ABCG2 Transporters. Assay and Drug Development Technologies. 6(2). 263–276. 52 indexed citations
20.
Ariazi, Eric A., Andrei Leitão, Tudor I. Oprea, et al.. (2007). Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Molecular Cancer Therapeutics. 6(11). 2817–2827. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ruben Abagyan Breakdown of academic impact, for papers by Jian Zhang Breakdown of academic impact, for papers by Sean Ekins Breakdown of academic impact, for papers by Hualiang Jiang Breakdown of academic impact, for papers by Oleg Trott Breakdown of academic impact, for papers by Michel F. Sanner Breakdown of academic impact, for papers by Stephen H. Bryant Breakdown of academic impact, for papers by John P. Overington Breakdown of academic impact, for papers by Holger Gohlke Breakdown of academic impact, for papers by Roderick E. Hubbard
Rankless by CCL
2026